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Modification of CCNU pharmacokinetics by misonidazole-
A major mechanism of chemosensitization in mice
F.Y.F. Lee & P. Workman
MRC Clinical Oncology and Radiotherapeutics Unit, MRC Centre, Hills Road, Cambridge CB2 2QH.
Summary We have investigated the effect of misonidazole (MISO) on the pharmacokinetics of 1-(2-
chloroethyl)-3-cyclohexyl-l-nitrosourea (CCNU) in mice. CCNU and its monohydroxylated metabolites were
measured using a high performance liquid chromatography (HPLC) method. In the absence of MISO the
plasma disappearance of CCNU was biphasic with a tf, of 2.3 min and a tq of 53 min. The
monohydroxylated metabolites of CCNU also followed biphasic clearance kinetics. A large single dose of
MISO (0.5mgg-'), given i.p. 30min prior to CCNU, prolonged the tla by a factor of 2.6 but had no effect on
tip In addition, the apparent volume of distribution was decreased by a factor of 1.6. Consequently, the
plasma area under the curve (AUCO .) was increased by a factor of 1.7 for CCNU and by a factor of 2.0 for
total nitrosourea (CCNU+monohydroxylated metabolites). The effects of MISO on CCNU kinetics were
dependent on MISO dose and plasma concentration and on the interval between MISO and CCNU
administration. The concentration of CCNU was measured in 4 tumours: the KHT, RIF-1 and EMT6 mouse
tumours, and the HT29 xenograft. For all 4 tumours, 0.5mgg-' MISO raised the tumour concentrations of
CCNU and total nitrosourea by a considerable amount (2-2.5 times). More detailed studies in the KHT
tumour demonstrated that there was a significant lag period before peak tumour CCNU concentrations were
reached, and that MISO increased the peak concentrations by a factor of about 2.4. In contrast, there was no
such lag period for the plasma and MISO did not increase the plasma peak CCNU concentrations. These
data strongly suggest that modification of the pharmacokinetics may be a major contributory factor in the
enhancement of CCNU cytotoxicity by large single doses of MISO in vivo.
Many studies have shown that electron affinic
radiation sensitizers such as misonidazole (MISO)
can enhance the cytotoxic efficacy of a number of
anti-cancer agents against tumours in mice (for
review see McNally, 1982; Siemann, 1982a). In most
cases, the enhancements were greater in tumours
than in normal tissues resulting in a therapeutic
gain. A number of clinical trials are now in
progress.
The mechanism of action by which MISO exerts
its chemosensitising effect is unknown, although a
number of possible mechanisms have been discussed
(Brown, 1982; Millar, 1982; Siemann, 1982a). In
view of the selective enhancement of tumour
toxicity, most investigators have favoured hypoxia-
mediated mechanisms acting at the cellular level,
e.g. inhibition of DNA repair processes or depletion
of intracellular thiols. However, studies in our
laboratory have shown that MISO also inhibits the
hepatic drug-metabolising enzymes suggesting that
the mechanism may involve changes in cytotoxic
drug pharmacokinetics (Workman & Twentyman
1982, Workman et al., 1983). Some evidence in
favour of altered pharmacokinetics has been
obtained for melphalan (Clutterbuck et al., 1982),
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BCNU and cyclophosphamide (Tannock, 1980), and
chlorambucil (Workman et al., 1983), but a
pharmacokinetic mechanism for therapeutic gain
has not yet been provided. We now present data
which show that MISO profoundly alters the
metabolism of CCNU and its active metabolites in
a way which appears to explain the
chemosensitization and therapeutic gain obtained
with large doses of MISO in mice.
Materials and methods
Drugs
MISO was supplied by Roche Products Ltd. and
CCNU by the Drug Synthesis and Chemistry
Branch of the National Cancer Institute, USA, and
by Lundbeck. The synthetic monohydroxylated-
CCNU metabolites were kindly given by Dr. T.P.
Johnston of the Southern Research Institute,
Alabama, U.S.A.
Mice and tumours
Inbred female C3H/He and male BALB/c mice were
supplied by OLAC. Male CBA nude mice were
supplied by NIMR (Mill Hill). KHT and RIF-1
tumours were grown in C3H mice, EMT6 tumours
in BALB/c mice and HT29 xenografts in CBA nude
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mice. KHT, RIF-1 and EMT6 tumours were grown
in the gastrocnemius muscles of the hind leg as
described by Twentyman et al. (1979). The HT29
human colonic adenocarcinoma xenograft was
grown bilaterally from s.c. injections in the flank as
described for the HT29R line by Warenius &
Bleehen (1982). Unless otherwise stated data
reported are for C3H/He mice.
Drug administration
CCNU was first dissolved in a 1:1 mixture of
ethanol/Cremophor-EL (Sigma) and then diluted 1:4
with saline. In this form CCNU remains stable for
at least 8h at room temperature as determined by
high-performance liquid chromatography (HPLC)
assay. This solution was injected in 0.01 mlg-
body weight.
MISO was dissolved in Hanks' balanced salt
solution and injected i.p. in 0.04mlg-' body
weight.
In most experiments mice received 0.5mgg- 1
(2.5mmolkg-') MISO followed by an appropriate
dose of CCNU 30 min later. In some experiments a
range of MISO doses (0.1-1.Omgg-1) was used,
while in others CCNU was given at varying
intervals (0.5-6h) after MISO. In all instances
controls were given the appropriate vehicles.
Sample preparation
Blood was drawn by heart puncture into
heparinized syringes (0.5-0.8 ml per mouse). This
was immediately cooled on ice and pooled with
blood from mice of the same group. The pooled
blood was immediately centrifuged in a refrigerated
Du Pont Sorvall RC-5B Superspeed Centrifuge (Du
Pont Instruments, U.S.A.) at 4000g for 10min. For
CCNU analysis, aliquots of plasma were extracted
with an equal volume of cold diethyl ether (HPLC
grade, Fisons). Aliquots of the supernatant were
evaporated to dryness in vacuo using a Savant
Speed Vac Concentrator coupled to a Model IOOA
Refrigerated Condensation Trap (Uniscience). The
dry residues were redissolved in 50pl ethanol
(Spectrograde, Fisons) and stored sealed at -20°C.
35pl of the ethanol concentrate was used for
HPLC analysis.
Tumours were excised rapidly and immediately
frozen to -70°C in an ethanol/dry ice freezing
mixture. A 20% (w/v) homogenate in distilled water
was then prepared using a 'Verso' Laboratory
Mixer Emulsifier (Silverson, U.K.). The homogenate
was then processed as for plasma.
Recovery from plasma and tumour homogenate
was consistently 100% for CCNU and 85% for the
major, trans-4-monohydroxylated metabolite, as
measured by HPLC. The recoveries were not
affected by MISO.
For MISO analysis aliquots of plasma were
precipitated with 4 vols of methanol (HPLC grade,
Rathburns) and cooled on dry ice. Following
centrifugation at 4000g for 10 min in a Sorvall RC-
5B Centrifuge, aliquots of supernatant were
removed for HPLC analysis.
High-performance liquid chromatography
Reversed-phase HPLC was used for both MISO
and CCNU analyses. The HPLC equipment
(Waters Associates, Milford, Mass., U.S.A.)
consisted of Model 6000A chromatography pumps,
Model 710B Automated Sample Processors (WISP),
Data Module, Model 720 System Controller, RCM-
100 Radial Compression Modules, and Model 440
u.v. absorbance detectors. Separations were carried
out on Waters Radial-PAK reverse-phase bonded
octadecylsilane (C18) cartridge columns (8mm I.D.,
5 pm or 10pum diameter spherical particles)
protected by Waters RCSS Guard-PAK C18
guard columns.
Analysis of MISO and its 0-demethylated
metabolite Ro 05-9963 was essentially as described
previously (Workman et al., 1978) but with minor
modifications for use with the Radial Compression
Module.
For CCNU analysis, samples were eluted by
running a two-step linear gradient commencing, at
the time of injection, with an initial condition of
34% acetonitrile (HPLC low u.v. absorbance grade,
Rathburns) in water (HPLC grade, Fisons) and
proceeding to 44% over 5 min and then to 64%
over another 7 min. Absorbance was monitored at
254nm.
With the above method the coefficients of
variation were 5.9% and 7.7% for trans-4-hydroxy
CCNU and CCNU respectively at a concentration
of 0.5pgml- . The lower limit of detection was
approximately 10ngml-.
Drugs and metabolites were identified by co-
chromatography with authentic synthetic standards
where available.
Protein binding
For in vivo binding studies, mice, with or without
MISO (0.5mgg-1) pretreatment, were sacrificed 15
min after i.p. injection of CCNU (20mgkg-1) and
the plasma from 4 mice was pooled. Separation of
plasma water from plasma protein was
accomplished by ultrafiltration across YMB
membranes using the Amicon Micropartition
System (Amicon, Woking, U.K.) in an MSE
Chilspin Centrifuge operating at 2000g. The
ultrafiltrate obtained was analysed as described
above for plasma. For in vitro binding studies
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incubated at 37°C for 15 min. Binding was then
determined as above.
Spontaneous chemical degradation
CCNU was incubated at 37°C at a concentration of
5pgml-1 in 0.1 M sodium phosphate buffer, pH
7.4, with or without MISO (0.5mgml-').
Concentrations of CCNU remaining at various
times were determined by HPLC.
Pharmacokinetic parameters
When appropriate, i.e. in regions where exponential
decays operated, best fit lines were estimated by
least squares regression analysis yielding half-lives
with 95% confidence limits. CCNU data were fitted
to the two compartment open model using the
method of curve stripping (Workman & Brown,
1981). Pharmacokinetic parameters were calculated
as described previously (Workman & Brown, 1981;
White & Workman, 1980). Values estimated for
Vdarea and clearance are apparent values assuming
100% bioavailability. Degree of significance was
calculated by Student's t-distribution.
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Results
Pharmacokinetics ofMISO in mice
Figure 1 shows the typical pharmacokinetics of
MISO given i.p. at a dose of 0.5mgg-'. CCNU, at
a dose of 20mgml- 1 i.p. administered 0.5 h
following MISO, had no significant effect on MISO
pharmacokinetics. The plasma decay curve gives an
apparent ti value (Workman, 1980a) of 0.95 (0.86-
1.02)h for mice also given CCNU, compared to 0.99
(0.87-1.06) h for the controls (P>0.1).
Concentrations of the metabolite Ro 05-9963 were
also unaffected (Figure 1).
HPLC ofCCNU and its metabolites
CCNU is metabolized rapidly by the liver
microsomal mixed function oxidase system to ring-
monohydroxylated products (Hilton & Walker
1975). Five of the 6 possible isomeric metabolites
were detected in the plasma of our mice. Figure 2 is
a representative HPLC chromatogram of the ether
extract of plasma obtained from mice treated with
20mgkg- 1 CCNU i.p. Peak 6 in Figure 2 is
CCNU. Peaks 1 and 5 co-chromatograph with
authentic standards of the trans-4 and trans-2
hydroxy CCNU isomers respectively. Montgomery
et aL (1976) using a very similar HPLC system
reported that the elution of the cis-trans pairs of
monohydroxylated CCNUs occurs in the order of
alternating diequatorial and axial-equatorial
Figure 1 The effect of 20mgkg- CCNU on the
pharmacokinetics of 0.5mgg-1 MISO and its
metabolite Ro 05-9963 0, A MISO and Ro 05-9963
alone respectively. 0, A MISO and Ro 05-9963
respectively with CCNU pretreatment. Each datum
point is for 3 mice.
isomers which reflects their partition coefficients:
thus the order is trans-4-hydroxy, cis-4-hydroxy, cis-
3-hydroxy, trans-3-hydroxy, trans-2-hydroxy and
cis-2-hydroxy CCNU. We have therefore assigned
peaks 2, 3 and 4 as the cis-4, cis-3 and trans-3-
hydroxy CCNU respectively.
Pharmacokinetics ofCCNU and the effects ofMISO
pretreatment
Figure 3 shows all the data obtained on the plasma
pharmacokinetics of CCNU in mice. Absorption of
an i.p. administered dose (20mgkg-1) was
extremely rapid, with peak plasma concentration
being reached within 2 min after injection. The
plasma clearance of CCNU follows biexponential
kinetics, with a rapid initial (a) phase followed by a
slower terminal (,B) phase. The c and ,B components
are normally regarded as the distribution and
elimination phases respectively. In this case a
considerable amount of metabolism occurs during
the ac-phase (see later), and the terminal elimination
may be limited by the rate of redistribution of
CCNU from tissue depots back into the plasma.
Figure 3 also shows the effects of 0.5mgg-'
MISO, given 30min before, on the plasma
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Figure 2 HPLC chromatogram of
metabolites in an ether extract of
15min after CCNU administration.
hydroxy-CCNU, peak 2: cis-4-hydr
3: cis-3-hydroxy-CCNU, peak 4:
CCNU, peak 5: trans-2-hydroxy-4
CCNU. The upper section shows the
pharmacokinetics of CCNU. The pharmacokinetic
parameters for CCNU are summarised in Table I.
The effect was highly reproducible with similar
results obtained in all 4 repeat experiments. The
half-life of the a phase (t4a) was increased from 2.3
(1.9-2.8) min to 5.8 (5.0-6.9) min (P<0.001),
wlhereas the half-life of the /3 phase (to#) was not
10 15 significantly changed (P>0.1), i.e. 53 (40.0-76.0)
min as compared with 56.1 (43.1-80.2) min in the
controls. However, the apparent volume of
distribution (App. Vdarea), a theoretical volume in
which a drug would be distributed in the body at
the same concentration as in the plasma, was
decreased by a factor of 1.6. The plasma area under
the curve (AUCO-_ ,) for CCNU was increased by a
factor of 1.7.
Effects of MISO pretreatment on the disposition of
CCNU metabolites
Five monohydroxylated metabolites were detected,
6 of which the trans-4-hydroxy and cis-4-hydroxy
metabolites represent -90% of the total. The trans-
2-hydroxy metabolite was present in trace amounts
(0.03yigml-') and only in early time points and will
not be considered further. The cis-2-hydroxy
'o 15 metabolite was not detected, and if present was
below a concentration of 0.01jIgml 1.
Metabolites were detected as early as 1 min after
CCNU and the CCNU administration. All 4 important metabolites
plasma obtained have a similar pattern of disposition (Figure 4).
oxy-CCNU, peak Maximum concentrations were reached within 10-
trans-3-hydroxy- 20 min following i.p. injection of 20mgkg1
CCNU, peak 6: CCNU. Thus most of the metabolism occurs during
gradient profile. the a-phase of CCNU clearance. The plasma
Table I Effect of 2.5mmolkg-1 MISO on the pharmacokinetic parameters of
CCNU (20mgkg-'). MISO was given 30min before CCNU. Calculated from
pooled data from 4 experiments
Parameters Control*t MISO*t
A (jugml ') 7.55 (4.70-11.89) 3.79 (2.77-5.19)
B (pgml-') 0.190 (0.110-0.331) 0.406 (0.256-0.645)
a (minm-) 0.307 (0.249-0.365) 0.119 (0.100-0.t39)
,B (min-') 0.013 (0.011-0.017) 0.012 (0.009-0.021)
t,, (min) 2.3 (1.9-2.8) 5.8 (5.0-6.9)
t,, (min) 53.0 (40.0-76.0) 56.1 (43.1-80.2)
AUCO_o (pgml-'min) 43.0 74.0
App. Clearance
(I kg- 1min-') 0.463 0.269
App. Vdarea
(1kg-1) 35.6 22.4
*The values were fitted to the two compartment open model: C,=Ae-t +Be-
t95% confidence limits in parentheses.
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Figure 3 The effect of 0.5mgg-1 MISO given 30 min before on the pharmacokinetics of CCNU. *, *, A,
V, * 20mgkg-' CCNU alone. O, 0, A, V, O 20mgkg-' after MISO. The data were obtained in 5
independent experiments, indicated by different symbols. Each datum point is for 3 mice.
clearance of the metabolites was biphasic in the
control mice. Values for the tya of the metabolites
could not be calculated with any precision because
of the scatter in the data due to their rapid
appearance and initial clearance. Values for y# and
AUCO are summarised in Table II.
Following MISO administration the clearance of
the main trans-4 hydroxy metabolites and of the
total nitrosoureas appeared to become monophasic,
whereas the clearance of the other metabolites
remained biphasic (Figure 4). Concentrations of all
the metabolites were increased by MISO. AUCOG-
Table II The effect of 0.5mgg-1 MISO on the terminal half-life and plasma area under the curve (AUCO_-,) of
CCNU metabolites following 20mgkg-' CCNU. MISO was given 30 min before CCNU. Calculated from pooled
data from 4 experiments.
Parameters Pretreatment Trans-4 Cis-4 Cis-3 Trans-3 Total
Terminal Control 86.4 91.7 108.1 64.3 94.2
tI# (min) (67.6A113.8) (65.9-150.8) (95.0125.4) (49.3-92.7) (72.4134.8)
MISO 84.8 76.7 109.6 68.2 85.2
(71.0-105.2) (58.5-111.4) (88.7-143.5) (52.4-97.8) (67.9-109.0)
AUCO Control 370 67 24 13 473
(ugml-'min) MISO 778 109 32 16 936
*95% confidence limits in parentheses.
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Figure 4 The effect of 0.5mgg- MISO given 30 min before on the pharmacokinetics of the total
nitrosoureas (e) and the 4 important monohydroxylated metabolites of CCNU after an i.p. dose of
20mgkg-' of the parent compound: (a) Trans 4; (b) Cis 3; (c) Cis 4; (d) Trans 3. Closed symbols (*, 0, A,
*) denote mice receiving CCNU alone, open symbols (0, 0, A, EJ) denote mice with MISO pretreatment.
The data were obtained in 4 independent experiments, indicated by different symbols. Each datum point is for
3 mice.
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values were elevated by MISO, particularly for the
trans-4 and cis-4 metabolites and the total
nitrosoureas (Table II). However the terminal ti values were not significantly altered by MISO
(P>0.1) indicating that the main effects occurred
during the production and initial clearance of the
metabolites. It should be noted that the peak
concentration of the total nitrosoureas was not
affected by MISO (Figure 4) whereas the AUCO0_
was increased by a factor of 2.
The lack of effects on the f-phase clearance is
consistent with the hypothesis that the rate-limiting
process of the fl-phase plasma clearance of CCNU
and metabolites is not hepatic metabolism but the
redistribution from tissue depots as adipose tissue
back into the plasma. A possible alternative
explanation was that the concentration of MISO in
plasma may have dropped below the inhibitory
level during the fl-phase. This was ruled out because
in an experiment where 0.5mgg1 MISO was given
during the early #-phase of CCNU clearance (1 h
after CCNU), there was again no significant change
in the ty (P>0.1, data not shown). However the
apparent volume of distribution again appeared to
be reduced.
CCNU dose modification by MISO
Figure 5 shows the concentrations of total
nitrosoureas in the plasma of mice given CCNU
(20mgkg 1) alone, CCNU (20mgkg 1) with MISO
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(0.5mgg- , 0.5h before) or CCNU (40mgkg-l)
alone. It can be seen that for the initial 60 min or
so after CCNU the plasma level of cytotoxic
nitrosoureas was substantially higher in the mice
that received 40mgkg- CCNU than those that
received 20mgkg- CCNU with MISO
(0.5mgkg- ) pretreatment. However, after this
initial period very similar values were found. The
two treatment regimes nevertheless gave very
similar values for plasma total nitrosoureas
AUCO-0: lO90pgml-P min for the higher CCNU
dose and 1000 gml-' min for the lower CCNU
dose with MISO pretreatment, compared to
502pgml- min for the lower dose alone. Thus the
dose-modifying factor (DMF) for drug exposure by
MISO was - 2, whereas the DMF for peak
concentration was very much less.
The dose-response ofMISO on CCNU clearance
The plasma clearance of CCNU was estimated after
varying MISO doses (0.05mgg-l_lmgg-') by
monitoring its plasma concentrations at a fixed time
(25 min after injection). Some typical results are
shown in Figure 6A. Plasma clearance of CCNU
was reduced as the MISO dose was increased, with
a threshold MISO dose at about 0.3mgg l.
The effects of varying the interval between
0.5mgg- MISO and CCNU administration are
shown in Figure 6B. MISO was found to be most
effective when given 0.5-1 h prior to CCNU. Its
effectiveness was reduced with increasing interval up
to 4h, and no effects were observed at 6h.
Effects of MISO on the CCNU concentrations in
tumours
Several experiments were carried out to determine
. oW the effect of MISO on the concentrations of CCNU
< \ in 3 transplantable mouse tumours (KHT, RIF-1
1 0 and EMT6) and the HT29 colon carcinoma
xenograft. Figure 7 shows all the data obtained.
The ratio of tumour/plasma CCNU concentrations
was tumour dependent: KHT and HT29 gave
relatively high ratios, EMT6 an intermediate, and
RIF-l a low ratio (Table III). Tumour/plasma
ratios were not altered by 0.5mgg-1 MISO (Table
III), but in all 4 tumours the CCNU concentrations
1 ldo | 280 250 were consistently higher after MISO. Similar 0 50 100 150 260 250 differences were seen with the hydroxylated
Time (min) metabolites (data not shown).
.e5Teds-oiynefeto05mg of More detailed experiments were carried out to
SO given 30dmin before on the plasma determine the initial tumour uptake in the KHT
rmacokinetics of nitrosoureas. 0 20mgkg-1 tumours (Figure 7). It was found that the peak
NU alone, 0 20mgkg-' with MISO pretreatment, tumour concentration lagged considerably behind
40mgkg-1 CCNU alone. Each datum point is for that of the peak plasma concentration suggesting a iice. compromised uptake by tumour, due possibly to666 F.Y.F. LEE & P. WORKMAN
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Figure 6(a) The dose-response of MISO on the
plasma concentration of CCNU 25 min after
20mgkg-1 CCNU. MISO was given 30 min before
CCNU. (b) The effect of varying the interval between
MISO (0.5mgg-1) and CCNU (20mgkg-1)
administration on the plasma CCNU concentration 25
min after 20mgkg-1 CCNU. Each datum point is for
2 mice. Dotted lines represent the concentrations of
CCNU in control mice.
TableIII Tumour/plasma ratios of CCNU and total nitro-
soureas 30min after an i.p. dose of 20mgkg 1 CCNU with
or without MISO pretreatment (0.5mgg-' 30min before
CCNU). Pooled data from several experiments.
Tmour/plasma ratio
Tumour Pretreatment CCNU Total nitrosoureas
KHT Control 1.20+0.19 0.8 +0.21
MISO 1.30+0.35 0.86+0.18
RIF-1 Control 0.30+0.08 0.24+0.05
MISO 0.40+0.08 0.22+0.03
EMT6 Control 0.58 +0.12 0.55+0.14
MISO 0.62+0.21 0.46+0.17
HT29 Control 0.77+0.14 0.61+0.13
MISO 1.03+0.19 0.70+0.20
Results shown are mean +2 s.e. of 3-6 determinations.
inadequate blood supply. MISO increased the peak
tumour concentration by a factor of - 2.4.
Binding ofCCNU to plasma protein
Table IV shows the extent to which CCNU and its
major metabolite, trans-4 monohydroxylated
CCNU, bind to mouse plasma proteins. At
concentrations up to 0.5mgml-1 (2.5mM) MISO
did not appear to affect the binding of the
nitrosoureas; this was found to be the case for both
in vivo and in vitro binding.
TableIV In vivo and in vitrobinding ofCCNU and trans-4-
hydroxy-CCNU to mouse plasma protein with and without
the presence of 0.5mgml-' MISO. Calculated from pooled
data from 2 experiments.
trans-4-hydroxy-
Pretreatment CCNU CCNU
% bound
in vitro MISO 94+2.5 53+2.2
+2 s.e.
(n =8) Control 96+ 1.5 49+2.9
% bound
in vivo MISO 90+ 3.7 53+4.7
+2 s.e.
(n =7) Control 93+2.1 51+3.4
None of the differences between MISO and control were
statistically significant (P>0.1).
Spontaneous chemical degradation of CCNU
CCNU undergoes spontaneous degradation in
aqueous solution to form non-u.v. absorbing
species. We have compared the chemical half-lives
of CCNU in 0.1 M PBS, pH 7.4, with and without
0.5mgml-1 (2.5mM) MISO. No significant
difference was found (P>0.1); the ti values were 43
(39-47) min and 40 (36-46) min respectively.
Discussion
The results of these studies clearly show that single
high doses of MISO reduced the rate of plasma
clearance of CCNU and its active metabolites. The
tumour concentrations of CCNU generally reflect
the plasma concentrations, and therefore MISO has
the effect of increasing the tumour exposure to the
cytotoxic nitrosoureas.*
The pharmacokinetics of CCNU, not described in
such detail previously, appear to involve a rapid
initial clearance due to metabolism to the
*It may be significant that the magnitude of the
tumour/plasma ratios of the 3 murine tumours KHT,
EMT6 and RIF-1 also reflect their in vivo sensitivity to
CCNU.
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Figure 7 The effect of 0.5mgg-1 MISO on the concentration of CCNU in (a) KHT, (b) RIF-1, (c) EMT6
and (d) HT29 tumours. Closed symbols 20mgkg-' CCNU alone. Open symbols 20mgkg-' CCNU with
0.5mgg-1 MISO 30 min before. Different symbols represent independent experiments. Each datum point is
for 2 or 3 tumours.
hydroxylated metabolites; this is followed by a
slower terminal clearance probably limited by slow
release of the highly lipophilic CCNU from
hydrophobic depots, such as adipose tissue. The
initial kinetics of the increased concentrations of
CCNU and its hydroxylated metabolites are
consistent with a model in which MISO inhibits the
hydroxylation of CCNU and may also inhibit the
subsequent metabolism of the hydroxylated
derivatives to unknown species. The increased levels
of CCNU at later times were due to a reduction in
the volume of distribution, and a similar effect may
also occur with the metabolites. The mechanism by
which MISO decreases the apparent volume of
distribution ofCCNU is notknown, but may involve a
reduced penetration of the drug into, or a reduced
retention by, certain body tissue depots. Both MISO
(Shoemakeretal., 1982)andthenitrosoureas(Walker&
Hilton 1976) are metabolized by the liver mixed
function oxidase enzymes and it is likely that MISO
may act as a competitive inhibitor of nitrosourea
metabolism. Experiments are in progress to determine
the nature of the inhibition in liver microsomal
preparations. The inhibition is not due to the
hypothermiaseenwithhigherdosesofMISO(Gomer&
Johnson, 1979),sincethedoseusedin thepresentstudy
does not alter the rectal temperature significantly.
Effects of MISO on protein binding and spontaneous
chemical degradation were also excluded by experi-
ments reported here.
Several authors have demonstrated selective
enhancement of murine tumour toxicity of CCNU
by large single doses of MISO and a therapeutic
gain is consistently observed (Hirst et al., 1982;
l i
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Siemann, 1981, 1982b; Twentyman & Workman
1982). The mechanism of action of MISO
chemosensitisation is not fully understood, but in
view of the increase in the plasma and tumour
levels of cytotoxic nitrosoureas by 0.5mgg-1
MISO it is likely that pharmacokinetic modification
is an important contributory mechanism. In
support of this we found that the MISO dose
needed to produce significant reduction of CCNU
clearance had to be >0.3mgg- , and this
correlates well with the doses required for effective
chemosensitisation. The effect of the timing of the
two drugs is also similar for pharmacokinetic
changes and chemosensitization.
Several other lines of evidence support the
pharmacokinetic mechanism. SKF-525-A, the
classical inhibitor of xenobiotic detoxification
enzymes, has been shown to produce excellent
enhancement of CCNU cytotoxicity (Workman &
Twentyman 1982; Siemann, 1983). We have also
demonstrated a therapeutic gain for this
combination (Workman & Twentyman, in
preparation), but Siemann (1983) found that the
normal tissue toxicity was also increased. Other
studies in our laboratory have clearly demonstrated
inhibition of drug metabolising enzymes by MISO
(Workman et al., 1983), and we have also shown
that MISO slows the clearance of chlorambucil and
melphalan (Workman et al., 1983, Lee & Workman
unpublished). Other laboratories have found that
MISO reduces the clearance of melphalan
(Clutterbuck et al., 1982; McNally et al., personal
communication) and the active metabolites of
cyclophosphamide and BCNU (Tannock, 1980;
McNally et al., personal communication).
Our results on the pharmacokinetics of CCNU
provide a possible explanation for the therapeutic
gain with the combination of MISO and CCNU.
MISO increased the peak tumour concentration of
CCNU and total nitrosoureas without increasing
the peak plasma concentration. This was due to the
fact that peak tumour levels lag behind the peak
plasma levels, probably because of inadequate
tumour blood supply. If the peak nitrosourea
concentration is more important for cytotoxicity
than overall exposure, and if the better perfused
dose-limiting normal tissues (gut and bone marrow)
follow the plasma concentration more closely than
the tumour, then the differential effect of MISO will
result in a therapeutic gain. We are now developing
methods to assay nitrosoureas in bone marrow and
gut.
Differences in the pharmacokinetics of various
nitrosoureas may provide an alternative explanation
for the interesting chemosensitization data of
Mulcahy (1982) who reported a good correlation
between the dose-modifying factor produced by
pretreatment with MISO and the relative
carbamoylating activities of individual nitrosoureas.
However, the order of relative carbamoylating
activities of the nitrosoureas studied also correlates
with increasing relative partition coefficient which
generally determines whether or not a drug is
metabolized by hepatic enzymes.
The important question is whether the MISO
effect can be obtained with clinically relevant doses.
The doses of MISO used in experimental studies
have generally been in the range of 0.3-lmgg-1
(1.5-5 mmol kg- ) giving peak plasma concentrations
of 300-1000jgml-1 (1.5-5 mM). In the clinic the
largest single dose normally given to patients
(3gm-2) produces a peak plasma concentration of
only 100pgml-1 (0.5mM) (Workman, 1980b).
However, the plasma half-life of MISO in man is
10-20 times longer than in the mouse (Workman,
1980b). We have therefore tried to mimic human
pharmacokinetics in mice by giving multiple small
doses of MISO (Brown & Hirst, 1982). Preliminary
results have indicated no appreciable change in
CCNU pharmacokinetics when plasma MISO
concentrations were maintained at about 90pgml-1
for over 4h prior to CCNU treatment (Lee &
Workman unpublished) and this probably explains
our observed lack of chemosensitization with this
regime (Twentyman & Workman, 1983). In
contrast, Brown & Hirst (1982) did observe
chemosensitization with this regime, and the
disparity may be due to the proximity of the MISO
plasma concentration to the threshold for changes
in pharmacokinetics and chemosensitization. In
experiments in the dog, which is a better model for
human MISO metabolism (White et al., 1979), a
relatively low dose of MISO (150mgkg-1 i.v.) given
immediately before CCNU (5mgkg 1 i.v.) has
produced significant changes in the clearance of
CCNU and its metabolites (Lee et al., unpublished).
We have recently found that the HPLC method
can be used to determine the pharmacokinetics of
CCNU and its metabolites in man, and this is now
being used to investigate the pharmacokinetic
interactions between nitroimidazoles and CCNU in
patients.
It should be emphasized that while the alterations
in CCNU pharmacokinetics by MISO described
here appear to explain the therapeutic gain for this
combination, we have at present no comparable
detailed data to support a similar mechanism for
the therapeutic gain seen with other cytotoxic
agents. We feel that poor penetration of cytotoxic
drugs into tumours at early times may be involved,
and experiments are in progress to test this.
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